Clinical utility of antigen carbohydrate 125 in heart failure

Heart Failure Reviews

Volumn 19, Issue 5, 2014, Pages 575-584

  Núñez, Julio ^a   Miñana, Gema ^a   Núñez, Eduardo ^a   Chorro, Francisco J ^a   Bodí, Vicent ^a   Sanchis, Juan ^a  

^a HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

Author keywords

Antigen carbohydrate 125; Biomarkers; Heart failure; Prognosis

Indexed keywords

CA 125 ANTIGEN; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NITROGEN; UREA; BIOLOGICAL MARKER;

AORTA VALVE DISEASE; DISEASE SEVERITY; HEART FAILURE; HEART HEMODYNAMICS; HUMAN; MONITORING; MORTALITY; PATHOPHYSIOLOGY; PERIPHERAL EDEMA; PLEURA EFFUSION; PROGNOSIS; REVIEW; RISK ASSESSMENT; TRANSCATHETER AORTIC VALVE IMPLANTATION; UREA NITROGEN BLOOD LEVEL; BLOOD; HEMODYNAMICS;

BIOLOGICAL MARKERS; CA-125 ANTIGEN; HEART FAILURE; HEMODYNAMICS; HUMANS; PROGNOSIS;

EID: 84906936407     PISSN: 13824147     EISSN: 15737322     Source Type: Journal    
DOI: 10.1007/s10741-013-9402-y     Document Type: Review

References (77)

1. Richards AM (2009) What we may expect from biomarkers in Heart Failure. Heart Fail Clin 5:463-470
2. Braunwald E (2008) Biomarkers in heart failure. N Engl J Med 358:2148-2159
3. Morrow DA, de Lemos JA (2007) Benchmarks for the assessment of novel cardiovascular biomarkers. Circulation 115:949-952 (Pubitemid 46328287)
4. Richards AM (2010) New biomarkers in heart failure: applications in diagnosis, prognosis and guidance of therapy. Rev Esp Cardiol 63:635-639
5. Palazzuoli A, Masson S, Ronco C, Maisel A (2013) Clinical relevance of biomarkers in heart failure and cardiorenal syndrome: the role of natriuretic peptides and troponin. Heart Fail Rev. doi:10.1007/s10741-013-9391-x
6. Hlatky MA, Greenland P, Arnett DK, Ballantyne CM, Criqui MH, Elkind MS, Go AS, Harrell FE Jr, Hong Y, Howard BV, Howard VJ, Hsue PY, Kramer CM, McConnell JP, Normand SL, O'Donnell CJ, Smith SC Jr, Wilson PW, American Heart Association Expert Panel on Subclinical Atherosclerotic Diseases and Emerging Risk Factors and the Stroke Council (2009) Criteria for evaluation of novel markers of cardiovascular risk: a scientific statement from the American Heart Association. Circulation 119:2408-2416
7. Zeillemaker AM, Verbrugh HA, Hoynck van Papendrecht AA, Leguit P (1994) CA 125 secretion by peritoneal mesothelial cells. J Clin Pathol 47:263-265 (Pubitemid 24120692)
8. Davis HM, Zurawski VR Jr, Bast RC Jr, Klug TL (1986) Characterization of the CA 125 antigen associated with human epithelial ovarian carcinomas. Cancer Res 46:6143-6148 (Pubitemid 17221746)
9. Canney PA, Moore M, Wilkinson PM, James RD (1984) Ovarian cancer antigen CA125: a prospective clinical assessment of its role as a tumor marker. Br J Cancer 50:765-769 (Pubitemid 15221441)
10. Miralles C, Orea M, España P, Provencio M, Sánchez A, Cantos B, Cubedo R, Carcereny E, Bonilla F, Gea T (2003) Cancer antigen 125 associated with multiple benign and malignant pathologies. Ann Surg Oncol 10:150-154 (Pubitemid 40485935)
11. Kui Wong N, Easton RL, Panico M, Sutton-Smith M, Morrison JC, Lattanzio FA, Morris HR, Clark GF, Dell A, Patankar MS (2003) Characterization of the oligosaccharides associated with the human ovarian tumor marker CA125. J Biol Chem 278:28619-28634 (Pubitemid 36935768)
12. Murdoch WJ, Van Kirk EA, Smedts AM (2006) Complementinhibiting effect of ovarian cancer antigen CA-125. Cancer Lett 236:54-57
13. Yoshimura M, Ihara Y, Ohnishi A, Ijuhin N, Nishiura T, Kanakura Y, Matsuzawa Y, Taniguchi N (1996) Bisecting N-acetylglucosamine on K562 cells suppresses natural killer cytotoxicity and promotes spleen colonization. Cancer Res 56:412-418 (Pubitemid 26026373)
14. Núñez J, Miñana G, González M, Garcia-Ramón R, Sanchis J, Bodí V, Núñez E, Chorro FJ, Llàcer A, Miguel A (2011) Antigen carbohydrate 125 in heart failure: not just a surrogate for serosal effusions? Int J Cardiol 146:473-474
15. Núñez J, Miñana G, Núñez E, Sanchis J (2011) Antigen carbohydrate 125 in heart failure: a promising clinical tool. Int J Cardiol 150:369-370
16. Ege MR, Zorlu A, Yilmaz MB (2011) CA-125 and heart failure. Int J Cardiol 147:453-454
17. Turk HM, Pekdemir H, Buyukberber S, Sevinc A, Camci C, Kocabas R, Tarakcioglu M, Buyukberber NM (2003) Serum CA 125 levels in patients with chronic heart failure and accompanying pleural fluid. Tumour Biol 24:172-175 (Pubitemid 37500565)
18. Varol E, Ozaydin M, Dogan A, Kosar F (2005) Tumour marker levels in patients with chronic heart failure. Eur J Heart Fail 7:840-843 (Pubitemid 41125903)
19. Epiney M, Bertossa C, Weil A, Campana A, Bischof P (2000) CA125 production by the peritoneum: in vitro and in vivo studies. Hum Reprod 15:1261-1265 (Pubitemid 30335947)
20. Seo T, Ikeda Y, Onaka H, Hayashi T, Kawaguchi K, Kotake C, Toda T, Kobayashi K (1993) Usefulness of serum CA125 measurement for monitoring pericardial effusion. Jpn Circ J 57:489-494 (Pubitemid 23285830)
21. Kosar F, Aksoy Y, Ozguntekin G, Ozerol I, Varol E (2006) Relationship between cytokines and tumour markers in patients with chronic heart failure. Eur J Heart Fail 8:270-274 (Pubitemid 44275312)
22. Núñez J, Sanchis J, Bodí V, Fonarow GC, Núñez E, Bertomeu-González V, Miñana G, Consuegra L, Bosch MJ, Carratalá A, Chorro FJ, Llàcer A (2010) Improvement in risk stratification with the combination of the tumor marker antigen carbohydrate 125 and brain natriuretic peptide in patients with acute heart failure. Eur Heart J 31:1752-1763
23. Topatan B, Basaran A (2010) CA-125 and heart failure: déjà vu or "still to be seen". Int J Cardiol 145:626-629
24. Huang F, Chen J, Liu Y, Zhang K, Wang J, Huang H (2012) New mechanism of elevated CA125 in heart failure: the mechanical stress and inflammatory stimuli initiate CA125 synthesis. Med Hypotheses 79:381-383
25. Miñana G, Núñez J, Sanchis J, Bodí V, Núñez E, Llàcer A (2010) CA125 and immunoinflammatory activity in acute heart failure. Int J Cardiol 145:547-548
26. Hamdy NM, Basaran A (2011) Relationship between pro-antiinflammatory cytokines, T-cell activation and CA 125 in obese patients with heart failure. Med Sci Monit 17:CR174-CR179
27. Núñez J, González M, Miñana G, Garcia-Ramón R, Sanchis J, Bodí V, Núñez E, Puchades MJ, Palau P, Merlos P, Llàcer A, Miguel A (2012) Continuous ambulatory peritoneal dialysis as a therapeutic alternative in patients with advanced congestive heart failure. Eur J Heart Fail 14:540-548
28. Colombo PC, Jorde UP (2010) The active role of venous congestion in the pathophysiology of acute decompensated heart failure. Rev Esp Cardiol 63:5-8
29. Gheorghiade M, Follath F, Ponikowski P, Barsuk JH, Blair JE, Cleland JG, Dickstein K, Drazner MH, Fonarow GC, Jaarsma T, Jondeau G, Sendon JL, Mebazaa A, Metra M, Nieminen M, Pang PS, Seferovic P, Stevenson LW, van Veldhuisen DJ, Zannad F, Anker SD, Rhodes A, McMurray JJ, Filippatos G, European Society of Cardiology; European Society of Intensive Care Medicine (2010) Assessing and grading congestion in acute heart failure: a scientific statement from the acute heart failure committee of the heart failure association of the European society of cardiology and endorsed by the European society of intensive care medicine. Eur J Heart Fail 12:423-433
30. Bonfils PK, Damgaard M, Taskiran M, Goetze JP, Norsk P, Gadsbøll N (2010) Impact of diuretic treatment and sodium intake on plasma volume in patients with compensated systolic heart failure. Eur J Heart Fail 12:995-1001
31. Dibbs Z, Thornby J, White BG, Mann DL (1999) Natural variability of circulating levels of cytokines and cytokine receptors in patients with heart failure: implications for clinical trials. J Am Coll Cardiol 33:1935-2012
32. Núñez J, Núñez E, Consuegra L, Sanchis J, Bodí V, Martínez-Brotons A, Bertomeu-González V, Robles R, Bosch MJ, Fácila L, Darmofal H, Llàcer A (2007) Carbohydrate antigen 125: an emerging prognostic risk factor in acute heart failure? Heart 93:716-721
33. D'Aloia A, Faggiano P, Aurigemma G, Bontempi L, Ruggeri G, Metra M, Nodari S, Dei Cas L (2003) Serum levels of carbohydrate antigen 125 in patients with chronic heart failure: relation to clinical severity, hemodynamic and Doppler echocardiographic abnormalities, and short-term prognosis. J Am Coll Cardiol 41:1805-1811 (Pubitemid 36584256)
34. Faggiano P, D'Aloia A, Brentana L, Bignotti T, Fiorina C, Vizzardi E, Dei Cas L (2005) Serum levels of different tumour markers in patients with chronic heart failure. Eur J Heart Fail 7:57-61 (Pubitemid 40092492)
35. Kouris NT, Zacharos ID, Kontogianni DD, Goranitou GS, Sifaki MD, Grassos HE, Kalkandi EM, Babalis DK (2005) The significance of CA125 levels in patients with chronic congestive heart failure. Correlation with clinical and echocardiographic parameters. Eur J Heart Fail 7:199-203 (Pubitemid 40215613)
36. Duman D, Palit F, Simsek E, Bilgehan K (2008) Serum carbohydrate antigen 125 levels in advanced heart failure: relation to B-type natriuretic peptide and left atrial volume. Eur J Heart Fail 10:556-559
37. Nägele H, Bahlo M, Klapdor R, Rödiger W (1999) Fluctuations of tumor markers in heart failure patients pre and post heart transplantation. Anticancer Res 19:2531-2534
38. Hung CL, Hung TC, Liu CC, Wu YJ, Kuo JY, Hou CJ, Yeh HI (2012) Relation of carbohydrate antigen-125 to left atrial remodeling and its prognostic usefulness in patients with heart failure and preserved left ventricular ejection fraction in women. Am J Cardiol 110:993-1000
39. Yilmaz MB, Zorlu A, Tandogan I (2011) Plasma CA-125 level is related to both sides of the heart: a retrospective analysis. Int J Cardiol 149:80-82
40. Nägele H, Bahlo M, Klapdor R, Schaeperkoetter D, Rödiger W (1999) CA 125 and its relation to cardiac function. Am Heart J 137:1044-1049
41. Ordu S, Ozhan H, Alemdar R, Aydin M, Caglar O, Yuksel H, Kandis H (2012) Carbohydrate antigen-125 and N-terminal probrain natriuretic peptide levels: compared in heart-failure prognostication. Tex Heart Inst J 39:30-35
42. Mansour IN, Napan S, Tarek Alahdab M, Stamos TD (2010) Carbohydrate antigen 125 predicts long-term mortality in African American patients with acute decompensated heart failure. Congest Heart Fail 16:15-20
43. Vizzardi E, D'Aloia A, Pezzali N, Bugatti S, Curnis A, Dei Cas L (2012) Long-term prognostic value of CA 125 serum levels in mild to moderate heart failure patients. J Card Fail 18:68-73
44. Monteiro S, Franco F, Costa S, Monteiro P, Vieira H, Coelho L, Oliveira L, Providência LA (2010) Prognostic value of CA125 in advanced heart failure patients. Int J Cardiol 140:115-118
45. Antonini-Canterin F, Popescu BA, Popescu AC, Beladan CC, Korcova R, Piazza R, Cappelletti P, Rubin D, Cassin M, Faggiano P, Nicolosi GL (2008) Heart failure in patients with aortic stenosis: clinical and prognostic significance of carbohydrate antigen 125 and brain natriuretic peptide measurement. Int J Cardiol 128:406-412
46. Varol E, Yücel H, Arslan A, Ozaydin M, Erdoǧan D, Doǧan A (2012) Elevated carbohydrate antigen 125 levels in patients with aortic stenosis: relation to clinical severity and echocardiographic parameters. Turk Kardiyol Dern Ars 40:309-315
47. Varol E, Ozaydin M, Altinbas A, Aslan SM, Dogan A, Dede O (2007) Elevated carbohydrate antigen 125 levels in hypertrophic cardiomyopathy patients with heart failure. Heart Vessels 22:30-33 (Pubitemid 46477187)
48. Karaca O, Guler GB, Guler E, Gunes HM, Alizade E, Agus HZ, Gol G, Kahveci G, Esen O, Esen AM, Turkmen M (2012) Serum carbohydrate antigen 125 levels in nonischemic dilated cardiomyopathy: a useful biomarker for prognosis and functional mitral regurgitation. Congest Heart Fail 18:144-150
49. Núñez J, Núñez E, Sanchis J, Bodí V, Fonarow GC, Miñana G, Palau P, Bertomeu-González V, Carratalá A, Mainar L, Chorro FJ, Llàcer A (2012) CA125 and BNP serial measurements for risk stratification following an episode of acute heart failure. Int J Cardiol 159:21-28
50. Miñana Escrivá G, Núñez J, Sanchis J, Bodi V, Núñez E, Chorro FJ, Llàcer A (2012) Carbohydrate antigen 125 serial measurements after an admission for acute heart failure and risk of early readmission. Med Clin (Barc) 139:479-486
51. Husser O, Nunez J, Nunez E, Holzamer A, Camboni D, Luchner A, Sanchis J, Bodi V, Riegger G, Schmid C, Hilker M, Hengstenberg C (2013) Tumor marker carbohydrate antigen 125 predicts adverse outcome after transcatheter aortic valve implantation. JACC Cardiovasc Interv 6:487-496
52. Prognostic value of changes in N-terminal pro-brain natriuretic peptide in Val-HeFT (Valsartan Heart Failure Trial), (2008) Prognostic value of changes in N-terminal pro-brain natriuretic peptide in Val-HeFT (Valsartan Heart Failure Trial). J Am Coll Cardiol 52:997-1003
53. Kubánek M, Goode KM, Lánská V, Clark AL, Cleland JG (2009) The prognostic value of repeated measurement of N-terminal pro- B-type natriuretic peptide in patients with chronic heart failure due to left ventricular systolic dysfunction. Eur J Heart Fail 11:367-377
54. Bidart JM, Thuillier F, Augereau C, Chalas J, Daver A, Jacob N, Labrousse F, Voitot H (1999) Kinetics of serum tumor marker concentrations and usefulness in clinical monitoring. Clin Chem 45:1695-1707 (Pubitemid 29477325)
55. O'Donoghue M, Braunwald E (2010) Natriuretic peptides in heart failure: should therapy be guided by BNP levels? Nat Rev Cardiol 7:13-20
56. Kjekshus J, Apetrei E, Barrios V, Böhm M, Cleland JG, Cornel JH, Dunselman P, Fonseca C, Goudev A, Grande P, Gullestad L, Hjalmarson A, Hradec J, Jánosi A, Kamenský G, Komajda M, Korewicki J, Kuusi T, Mach F, Mareev V, McMurray JJ, Ranjith N, Schaufelberger M, Vanhaecke J, van Veldhuisen DJ, Waagstein F, Wedel H, Wikstrand J, CORONA Group (2007) Rosuvastatin in older patients with systolic heart failure. N Engl J Med 357:2248-2261 (Pubitemid 350190755)
57. Gissi-HF Investigators, Tavazzi L, Maggioni AP, Marchioli R, Barlera S, Franzosi MG, Latini R, Lucci D, Nicolosi GL, Porcu M, Tognoni G (2008) Effect of rosuvastatin in patients with chronic heart failure (the gissi-hf trial): a randomised, doubleblind, placebo-controlled trial. Lancet 372:1231-1239
58. McMurray JJ, Kjekshus J, Gullestad L, Dunselman P, Hjalmarson A, Wedel H, Lindberg M, Waagstein F, Grande P, Hradec J, Kamenský G, Korewicki J, Kuusi T, Mach F, Ranjith N, Wikstrand J, CORONA Study Group (2009) Effects of statin therapy according to plasma high-sensitivity C-reactive protein concentration in the controlled rosuvastatin multinational trial in heart failure (CORONA): a retrospective analysis. Circulation 120:2188-2196
59. Takano H, Mizuma H, Kuwabara Y, Sato Y, Shindo S, Kotooka N, Fujimatsu D, Kobayashi Y, Inoue T, Node K, Komuro I, PEARL Study Investigators (2013) Effects of pitavastatin on Japanese patients with chronic heart failure: the Pitavastatin Heart Failure Study (PEARL Study). Circ J 77:917-925
60. Núñez J, Sanchis J, Núñez E, Fonarow GC, Bodí V, Bertomeu-González V, Miñana G, Palau P, Fácila L, Chorro FJ, Bertomeu-Martínez V, Llàcer A (2011) Benefits of statin therapy according to plasma antigen carbohydrate 125 following an admission for acute heart failure. Rev Esp Cardiol 64:1100-1108
61. McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Böhm M, Dickstein K, Falk V, Filippatos G, Fonseca C, Gomez-Sanchez MA, Jaarsma T, Køber L, Lip GY, Maggioni AP, Parkhomenko A, Pieske BM, Popescu BA, Rønnevik PK, Rutten FH, Schwitter J, Seferovic P, Stepinska J, Trindade PT, Voors AA, Zannad F, Zeiher A, Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology, Bax JJ, Baumgartner H, Ceconi C, Dean V, Deaton C, Fagard R, Funck-Brentano C, Hasdai D, Hoes A, Kirchhof P, Knuuti J, Kolh P, McDonagh T, Moulin C, Popescu BA, Reiner Z, Sechtem U, Sirnes PA, Tendera M, Torbicki A, Vahanian A, Windecker S, McDonagh T, Sechtem U, Bonet LA, Avraamides P, Ben Lamin HA, Brignole M, Coca A, Cowburn P, Dargie H, Elliott P, Flachskampf FA, Guida GF, Hardman S, Iung B, Merkely B, Mueller C, Nanas JN, Nielsen OW, Orn S, Parissis JT, Ponikowski P, ESC Committee for Practice Guidelines (2012) ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the task force for the diagnosis and treatment of acute and chronic heart failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 14:803-869
62. Tsouli SG, Liberopoulos EN, Goudevenos JA, Mikhailidis DP, Elisaf MS (2008) Should a statin be prescribed to every patient with heart failure? Heart Fail Rev 13:211-225 (Pubitemid 351445343)
63. Anker SD, Clark AL, Winkler R, Zugck C, Cicoira M, Ponikowski P, Davos CH, Banasiak W, Zardini P, Haass M, Senges J, Coats AJ, Poole-Wilson PA, Pitt B (2006) Statin use and survival in patients with chronic heart failure - results from two observational studies with 5200 patients. Int J Cardiol 112:234-242 (Pubitemid 44376681)
64. McMurray JJ, Kjekshus J, Gullestad L, Dunselman P, Hjalmarson A, Wedel H, Lindberg M, Waagstein F, Grande P, Hradec J, Kamenský G, Korewicki J, Kuusi T, Mach F, Ranjith N, Wikstrand J, CORONA Study Group (2009) Effects of statin therapy according to plasma high-sensitivity c-reactive protein concentration in the controlled rosuvastatin multinational trial in heart failure (corona): a retrospective analysis. Circulation 120:2188-2196
65. Felker GM, O'Connor CM, Braunwald E, Heart Failure Clinical Research Network Investigators (2009) Loop diuretics in acute decompensated heart failure: necessary? Evil? A necessary evil? Circ Heart Fail 2:56-62
66. Eshaghian S, Horwich TB, Fonarow GC (2009) Relation of loop diuretic dose to mortality in advanced heart failure. Am J Cardiol 97:1759-1764 (Pubitemid 43817867)
67. Ahmed A, Husain A, Love TE, Gambassi G, Dell'Italia LJ, Francis GS, Gheorghiade M, Allman RM, Meleth S, Bourge RC (2006) Heart failure, chronic diuretic use, and increase in mortality and hospitalization: an observational study using propensity score methods. Eur Heart J 27:1431-1439 (Pubitemid 43998077)
68. Núñez J, Núñez E, Miñana G, Bodí V, Fonarow GC, Bertomeu-González V, Palau P, Merlos P, Ventura S, Chorro FJ, Llàcer P, Sanchis J (2012) Differential mortality association of loop diuretic dosage according to blood urea nitrogen and carbohydrate antigen 125 following a hospitalization for acute heart failure. Eur J Heart Fail 14:974-984
69. Mullens W, Abrahams Z, Francis GS, Sokos G, Taylor DO, Starling RC, Young JB, Tang WH (2009) Importance of venous congestion for worsening of renal function in advanced decompensated heart failure. J Am Coll Cardiol 53:589-596
70. Damman K, Ng Kam Chuen MJ, MacFadyen RJ, Lip GY, Gaze D, Collinson PO, Hillege HL, van Oeveren W, Voors AA, van Veldhuisen DJ (2011) Volume status and diuretic therapy in systolic heart failure and the detection of early abnormalities in renal and tubular function. J Am Coll Cardiol 57:2233-2241
71. van Kimmenade RR, Januzzi JL Jr (2012) Emerging biomarkers in heart failure. Clin Chem 58:127-138
72. Schmitter D, Cotter G, Voors AA (2013) Clinical use of novel biomarkers in heart failure: towards personalized medicine. Heart Fail Rev. doi:10.1007/s10741-013-9396-5
73. Gaggin HK, Januzzi JL Jr (2013) Biomarkers and diagnostics in heart failure. Biochim Biophys Acta. doi:10.1016/j.bbadis.2012.12.014
74. Gullestad L, Ueland T, Vinge LE, Finsen A, Yndestad A, Aukrust P (2012) Inflammatory cytokines in heart failure: mediators and markers. Cardiology 122:23-35
75. Araújo JP, Lourenço P, Azevedo A, Friões F, Rocha-Gonçalves F, Ferreira A, Bettencourt P (2009) Prognostic value of highsensitivity C-reactive protein in heart failure: a systematic review. J Cardiac Fail 15:256-266
76. Sherwi N, Merali S, Wong K (2012) Personalizing biomarker strategies in heart failure with galectin-3. Future Cardiol 8:885-894
77. Bhardwaj A, Januzzi JL Jr (2010) ST2: a novel biomarker for heart failure. Expert Rev Mol Diagn 10:459-464